Rosuvastatin Calcium Tablet, Film Coated
Product Images NDC 82804-291

This text provides statistical information related to a study or trial, including HR (Hazard Ratio) with a confidence interval, p-value for significance, cumulative incidence percentages, and the number at risk in different groups (possibly for various time points). The data includes values for both the treatment group and the placebo group.*

This text presents the results of a study comparing the effects of Rosuvastatin 20 mg versus placebo on various cardiovascular events. The study included 8901 participants in each group. The results show a significant reduction in the primary endpoint (Major Cardiovascular Events) in the Rosuvastatin group compared to placebo (HR 0.56, p<0.001). Additionally, there were lower rates of cardiovascular death, nonfatal stroke, nonfatal MI, unstable angina, and arterial revascularization in the Rosuvastatin group compared to the placebo group. The study suggests that Rosuvastatin 20 mg is effective in reducing the risk of cardiovascular events compared to placebo.*

This text provides information about Rosuvastatin 10mg tablets, each containing rosuvastatin calcium equivalent to 10 mg. The tablets are pink in color, film-coated, circular, and imprinted with "G*" on one side and "D" on the other. The product ID is ZR029130, distributed by Glenmark Pharmaceuticals Inc. in the USA. The tablets are packaged by Proficient Rx LP in Thousand Oaks, CA. The recommended storage temperature is 20°-25°C. The text also includes the National Drug Code (NDC) 82804-291-30, lot numbers, expiration date, and GTIN code for identification.*